Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8262235 | 1.00 | F10 (0.75) | F10KCNH2 | |
| SCHEMBL3957940 | 1.00 | F10 (0.75) | F10KCNH2 | |
| SCHEMBL1027607 | 1.00 | F10 (0.75) | F10KCNH2 | |
| SCHEMBL12955988 | 0.92 | F10 (0.77) | F10KCNH2 | |
| SCHEMBL8262259 | 0.92 | F10 (0.74) | F10KCNH2 | |
| SCHEMBL1030507 | 0.92 | F10 (0.77) | F10KCNH2 | |
| SCHEMBL8261666 | 0.91 | F10 (0.73) | F10KCNH2 | |
| SCHEMBL1029732 | 0.91 | F10 (0.73) | F10KCNH2 | |
| SCHEMBL8261715 | 0.91 | F10 (0.75) | F10KCNH2 | |
| SCHEMBL12955797 | 0.90 | F10 (0.71) | F10KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814855-B1 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | BOEHRINGER MARKUS | 2009-10-29 | — | — | US | disclosed |
| US-7501413-B2 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20060106016-A1 | Dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106016-A1 | Dicarboxamide derivatives | F2, F12, TFPI | F10 8/4885KCNH2 1702/4885 |
| US-20090270360-A1 | DICARBOXAMIDE DERIVATIVES | F2, F12, TFPI | F10 8/4885KCNH2 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.